Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

(2020) Tait D. Shanafelt et al.   BLOOD

Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies

(2019) Kerry A. Rogers et al.   LEUKEMIA

Improving attribution of adverse events in oncology clinical trials

(2019) Goldy C. George et al.   CANCER TREATMENT REVIEWS

Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis

(2018) Amelia Bercusson et al.   BLOOD

Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections

(2018) Talal Hilal et al.   BLOOD REVIEWS

A method to summarize toxicity in cancer randomized clinical trials

(2018) Mariana Carbini et al.   CLINICAL CANCER RESEARCH

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2

(2018) Paul M. Barr et al.   HAEMATOLOGICA

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2

(2018) Paul M. Barr et al.   HAEMATOLOGICA

The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy

(2018) Claudia SEW Schuurhuizen et al.   Cancer Management and Research

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

(2018) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

(2016) Barbara Eichhorst et al.   LANCET ONCOLOGY

The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials

(2015) Gita Thanarajasingam et al.   JNCI-Journal of the National Cancer Institute

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

(2015) Jan A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials

(2015) Gita Thanarajasingam et al.   JNCI-Journal of the National Cancer Institute

Adverse Event Reporting in Cancer Clinical Trial Publications

(2013) Shanthi Sivendran et al.   JOURNAL OF CLINICAL ONCOLOGY

Toxicity burden score: a novel approach to summarize multiple toxic effects

(2011) S. M. Lee et al.   ANNALS OF ONCOLOGY

Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2011) B. Eichhorst et al.   ANNALS OF ONCOLOGY

Evaluation of the Value of Attribution in the Interpretation of Adverse Event Data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group Investigation

(2010) Shauna L. Hillman et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

(2009) B. F. Eichhorst et al.   BLOOD